Literature DB >> 2512863

Risk factors for thrombosis in lupus patients.

P Hasselaar1, R H Derksen, L Blokzijl, M Hessing, H K Nieuwenhuis, B N Bouma, P G De Groot.   

Abstract

Lupus anticoagulant, concentrations of anticardiolipin antibodies, antithrombin III, plasminogen, (free) protein S, protein C, prothrombin, platelet counts, and bleeding times were determined in 74 lupus patients (58 with systemic lupus erythematosus; 16 with lupus-like disease) to establish the presence of risk factors for thrombosis in these patients. Of the variables evaluated, lupus anticoagulant had the strongest association with a history of thrombosis. Both positive anticardiolipin antibody concentrations and the presence of (mild) thrombocytopenia were significantly associated with a history of thrombosis and the presence of lupus anticoagulant. Reduced concentrations of antithrombin III, plasminogen, (free) protein S, and protein C were found in some patients but were not associated with either thrombosis or lupus anticoagulant. Mean concentrations of total protein S were significantly lower in patients with thrombosis than in those without and in patients with lupus anticoagulant than in those without. The antigenic concentration of prothrombin was reduced in 3/74 (4%) lupus patients. These three patients had lupus anticoagulant but no history of thrombosis, which suggests that a low prothrombin concentration protects patients with lupus anticoagulant from the development of thrombosis. A prolonged bleeding time was associated with the presence of lupus anticoagulant but not with a history of thrombosis. Analysis by stepwise logistic regression did not disclose additional risk factors for thrombosis in lupus patients with lupus anticoagulant. Increased antithrombin III concentrations and decreased free protein S concentrations are often found in lupus patients, unrelated to lupus anticoagulant or thrombosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512863      PMCID: PMC1003917          DOI: 10.1136/ard.48.11.933

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  27 in total

1.  The striking association between lupus anticoagulant and fetal loss in systemic lupus erythematosus patients.

Authors:  R H Derksen; B N Bouma; L Kater
Journal:  Arthritis Rheum       Date:  1986-05

2.  Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus.

Authors:  M A Byron; M J Allington; H M Chapel; A G Mowat; S A Cederholm-Williams
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

3.  Oral contraceptives reduce total protein S, but not free protein S.

Authors:  I A Huisveld; J E Hospers; J C Meijers; A E Starkenburg; W B Erich; B N Bouma
Journal:  Thromb Res       Date:  1987-01-01       Impact factor: 3.944

4.  Lupus anticoagulant, thrombosis, and fetal loss.

Authors:  D I Feinstein
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

Review 5.  Lupus anticoagulants.

Authors:  S S Shapiro; P Thiagarajan
Journal:  Prog Hemost Thromb       Date:  1982

6.  The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus.

Authors:  R H Derksen; B N Bouma; L Kater
Journal:  Scand J Rheumatol       Date:  1987       Impact factor: 3.641

7.  Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients.

Authors:  H K Nieuwenhuis; J W Akkerman; J J Sixma
Journal:  Blood       Date:  1987-09       Impact factor: 22.113

8.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

9.  An abnormal plasma distribution of protein S occurs in functional protein S deficiency.

Authors:  P C Comp; D Doray; D Patton; C T Esmon
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

Review 10.  Lupus anticoagulant: revival of an old phenomenon.

Authors:  R H Derksen; L Kater
Journal:  Clin Exp Rheumatol       Date:  1985 Oct-Dec       Impact factor: 4.473

View more
  4 in total

1.  Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids.

Authors:  H S Markus; N Hopkinson
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

Review 2.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

3.  Very long charge runs in systemic lupus erythematosus-associated autoantigens.

Authors:  V Brendel; J Dohlman; B E Blaisdell; S Karlin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

4.  Potential Involvement of Platelet-Derived Microparticles and Microparticles Forming Immune Complexes during Monocyte Activation in Patients with Systemic Lupus Erythematosus.

Authors:  Catalina Burbano; Juan Villar-Vesga; Janine Orejuela; Carlos Muñoz; Adriana Vanegas; Gloria Vásquez; Mauricio Rojas; Diana Castaño
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.